Category - Developments

Developments

111 Inc. posts 64.7% increase in Q1 net revenue

111 Inc. (NASDAQ:YI), a leading digital healthcare platform in China, posted net revenue of RMB2.6 billion ($396-million U.S.) for the first quarter of 2021, an increase of 64.7%, compared with the same quarter in 2020...

May 19, 2021

Developments

KA Imaging installs 2 mobile X-ray units at University Health Network

Closely-held KA Imaging installed two new mobile X-ray units in the University Health Network of Toronto to enhance current clinical studies and support patient care, with one unit is being used at the Princess Margaret...

May 18, 2021

Developments

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Seelos Therapeutics (NASDAQ:SEEL) reported positive data from Part 1, the open-label cohort, of its potentially registrational proof-of-concept study of SLS-002, demonstrating a significant treatment effect and a well...

May 17, 2021

Developments

Arctic Vision in exclusive licensing pact with ActualEyes

Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of...

May 14, 2021

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Developments

IntelGenx expands psychedelics accord with atai

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a second feasibility agreement with atai Life Sciences AG for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being...

May 12, 2021

Developments

Clene presents positive Phase 2 interim ALS efficacy data

Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...

May 12, 2021

Developments

RNA Disease Diagnostics inaugural board of directors and advisory board meet

Closely-held RNA Disease Diagnostics held an inaugural joint meeting of its board of directors and advisory board, which will work alongside the leadership team to advance the company’s proprietary antisense RNA...

May 11, 2021

Developments

IntelGenx shareholders approve atai Life Sciences investment

Shareholders at a virtual annual meeting of IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) approved atai Life Sciences AG’s investment in IntelGenx. Under the accord, atai initially will acquire an approximate 25%...

May 11, 2021

Developments

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...

May 7, 2021

Category - Developments

111 Inc. posts 64.7% increase in Q1 net revenue

KA Imaging installs 2 mobile X-ray units at University Health Network

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Arctic Vision in exclusive licensing pact with ActualEyes

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

IntelGenx expands psychedelics accord with atai

Clene presents positive Phase 2 interim ALS efficacy data

RNA Disease Diagnostics inaugural board of directors and advisory board meet

IntelGenx shareholders approve atai Life Sciences investment

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

General

More